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Summary Study objective: To assess the effect of topiramate (TPM) on body mass
index (BMI) in paediatric epilepsy patients and to examine predictors of weight loss.
Design: Retrospective, observational study. Setting: University clinic epilepsy outpa-
tient department. Subjects: Patients below age 18 years who received TPM for at
least 12 months. Measurements and main results: Changes in BMI (kg/m2) standard
deviation scores (S.D.S.) from baseline to the follow-up periods of 12, 24 and 36
months were evaluated. The repeated measures t-test for paired samples, revealed
signiﬁcant decreases for BMI S.D.S. at 12 months (P = 0.004; n = 53) and 24 months
(P = 0.044; n = 35), but no signiﬁcant decrease at 36 months (n = 21). Analysis of
variance revealed a predictor value of sex for BMI S.D.S. at 12 months (females more
likely to lose weight; P = 0.037) and a predictor value of baseline BMI for BMI S.D.S.
at 24 months (patients with a higher baseline BMI were more likely to lose weight;
P = 0.047). Conclusion: Weight loss is common in paediatric epilepsy patients who
receive TPM and is sustained for at least one year. The pattern of weight loss differs
according to sex and baseline BMI.
© 2003 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
Introduction
Changes in body weight are a signiﬁcant side
effect of the long-term administration of some
anti-epileptic drugs (AEDs).1 A signiﬁcant weight
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loss has been reported in connection with topira-
mate (TPM).2 Data on body mass index (BMI, weight
in kilograms/height in meters2) parameters, in-
cluding the standard deviation score (S.D.S.), of
children and adolescents during TPM therapy are
not available. The BMI is a standardized method of
assessing body weight in all stages of life, including
childhood, adolescence and adulthood.3 The ob-
jective of this retrospective analysis was to assess
1059-1311/$30 — see front matter © 2003 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.seizure.2003.12.001
492 E. Reiter et al.
Table 1 Age, weight standard deviation scores (S.D.S.) and BMI S.D.S. at baseline and follow-up.
Characteristics Baseline Follow-up
12 months 24 months 36 months
Number of patients N = 53 N = 53 N = 35 N = 21
Measured values
Age (years)
Mean ± S.D. 7.26 ± 5.21 8.23 ± 5.17 10.15 ± 5.38 12.21 ± 5.37
Standard deviation scores
Weight (kg)
Mean ± S.D. 0.35 ± 1.69 −0.10 ± 1.53a −0.18 ± 1.59b −0.11 ± 1.56a
Body mass index (kg/m2)
Mean ± S.D. 0.19 ± 1.24 −0.13 ± 1.36b −0.03 ± 1.36 −0.13 ± 1.45
Statistics: (a) P < 0.01, (b) P < 0.05 (repeated measures t-test).
the effect of long-term topiramate therapy on BMI
parameters in paediatric epilepsy patients and to
examine predictors of weight loss.
Subjects
Children and adolescents aged ≤18 years, who had
been commenced on TPM and who were treated
for at least 12 consecutive months, were identi-
ﬁed by searches of the study centre data-base. Sub-
jects who fulﬁlled these criteria were evaluated for
changes in BMI S.D.S. from baseline to the follow-up
periods of 12, 24 and 36 months.
The maximum daily dose of topiramate (given in
mg/kg body weight) was computed for each subject
during the period of therapy initiation and at the
last follow-up visit.
Methods
The BMI (kg/m2) was calculated for each individ-
ual patient. Age- and sex-speciﬁc developmental
changes in BMI, which are due to physiological al-
terations in fat mass, need to be addressed in chil-
dren and adolescents.3
Using the LMS method described by Cole,4 stan-
dard deviation scores (S.D.S.-LMS) can be cal-
culated by the following formula: S.D.S.LMS =
[BMI/M(t)]L(t) − 1/[L(t)× S(t)]. In this formula BMI
is the individual parameter, whereas M(t), L(t) and
S(t) are parameters for the age (t) and gender of
the child.3 The L curve (Box-Cox power to remove
skewness), the M curve (median) and the S curve
(coefﬁcient of variation) provide information to
draw any centile curve, and to convert measure-
ments (even extreme values) into exact standard
deviation scores.4
This formula was used in the present study to
calculate age- and sex-corrected S.D.S. of the BMI.
These scores express the degree of deviation for
any single individual BMI from the mean (=50th BMI
percentile) in terms of the number of standard de-
viations and offer a unique opportunity to compare
age- and sex-related changes in BMI over time. The
signiﬁcance of differences between these measures
was calculated using a repeated measures t-test
for paired samples if appropriate, Wilcoxon’s test if
values were not normally distributed, and one-way
ANOVA.
Results
A total of 53 subjects (male/female ratio: 25/28)
were included in the study. At the initiation of
treatment the subjects ranged in age from 0.5
to 17 years (median 6.5 years; mean 7.3 years).
According to Classiﬁcation scheme of the ILAE,
73.6 % (n = 39) had symptomatic, 11.3% (n = 6)
cryptogenic and 15.1% (n = 8) idiopathic epilepsy.
Of 53 patients, 5 received TPM as monother-
apy at the last visit and 48 received TPM as ad-
junctive therapy along with one (n = 42) or two
(n = 6) concomitant AEDs. The background AEDs
were as follows: valproic acid (n = 22), vigabatrin
(n = 9), phenobarbital/primidone (n = 8), car-
bamazepine/oxcarbazepine (n = 6), lamotrigine
(n = 5) and felbamate (n = 1). At the end of 12
months, 53 patients remained on TPM. TPM ther-
apy was given to 35 patients at 24 months, and to
21 patients at 36 months. This reduction was due
to either inefﬁcacy or adverse effects.
Changes in body mass index 493
The mean maximum daily dose of TPM was
8mg/kg body weight (BW) (range, 1—20mg/kg BW).
56.6% (n = 30) of the patients were seizure-free
at the last visit. No subject was on a special diet
or on an exercise program and no formal dietary
intervention was conducted during the study.
The age of the patients, weight S.D.S. and BMI
S.D.S. at baseline and follow-up (12, 24 and 36
months) are shown in Table 1.
Statistical S.D.S. comparisons between baseline
and follow-up, done by a repeated measures t-test
for paired samples, revealed signiﬁcant decreases
for BMI S.D.S. at 12 months (P = 0.004) and 24
months (P = 0.044), but no signiﬁcant decrease
at 36 months. ANOVA revealed a predictor value
of sex for BMI S.D.S. at 12 months (females more
likely to lose weight; P = 0.037) and a predictor
value of baseline BMI for BMI S.D.S. at 24 months
(patients with a higher baseline BMI were more
likely to lose weight; P = 0.047). BMI S.D.S. at 36
months tended to be lower for a higher baseline
BMI (P = 0.064). Age, maximum dosage of TPM and
number of AEDs had no predictor value. Despite
signiﬁcant decreases in BMI S.D.S. after 12 and 24
months of TPM treatment, no patient discontinued
topiramate therapy.
Discussion
A higher BMI at the start of treatment (with no pref-
erence for female/male patients or valproic acid
as concomitant AED) seems to be a predictor for
weight loss during TPM treatment; patients with a
higher BMI are more likely to lose weight. Accord-
ingly, in an adult clinical trial, weight loss after 1
year of TPM treatment was most strongly correlated
with a higher baseline BMI (P = 0.0007).5
In this study, paediatric epilepsy patients re-
vealed statistically signiﬁcant decreases in the BMI
S.D.S. after 12 and 24 months of TPM treatment
compared to baseline BMI S.D.S., which is indica-
tive of the sustained effect of TPM on BMI up to 2
years. Results of the present study are somewhat
different from those reported by Riviello et al.6
in which weight loss generally occurred early in
therapy–—although the time point was not speciﬁed–
—and a resumption of weight gain was reported
typically after 6 months of continued TPM therapy;
whereas Levison2 reported that weight loss oc-
curred in the ﬁrst 12—18 months, after which time
the patient resumes his/her normal weight gain.
Although in this study, subjects had a lower BMI
S.D.S. at the 36-month follow up compared to the
baseline BMI S.D.S., the difference was not statisti-
cally signiﬁcant. This may have been either due to
the small sample size at 36 months, or to cessation
of weight loss, or even a resumption of weight gain
between 24 and 36 months of TPM therapy. Despite
signiﬁcant decreases in BMI S.D.S. after 12 and 24
months of TPM treatment, weight loss did not ne-
cessitate drug withdrawal in any patient, which is
concordant with the current literature.2
In summary, regular calculation of BMI during
TPM therapy, especially in infancy, early childhood
and in mentally retarded/neurological impaired
children, offers a quantitative tool to monitor
changes in BMI over time. These measurements
should be conducted while monitoring paediatric
epilepsy patients so that changes may be detected
before the onset of serious adverse consequences
on the patients’ physical maturation.
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